open access

Vol 72, No 1 (2021)
Review paper
Published online: 2021-02-26
Submitted: 2020-12-19
Accepted: 2020-12-20
Get Citation

Expression of miRNA in obesity and insulin resistance: a review

Paulina Estrella Ibarra, Pablo García-Solís, Juan Carlos Solís-Sáinz, Andrés Cruz-Hernández
DOI: 10.5603/EP.a2021.0002
·
Pubmed: 33749820
·
Endokrynologia Polska 2021;72(1):73-80.

open access

Vol 72, No 1 (2021)
Review Article
Published online: 2021-02-26
Submitted: 2020-12-19
Accepted: 2020-12-20

Abstract

MicroRNAs (miRNAs) are part of the epigenetic mechanisms that regulate gene expression at a post-transcriptional level. This review describes some miRNAs whose expression is modified in obesity and that may be involved in the development of insulin resistance. The metabolic alterations associated with obesity are due to an adipose tissue dysfunction. miRNAs are a mechanism that regulates gene expression, one miRNA can regulate the expression up to a thousand genes, and at the same time one gene can be regulated by several miRNAs; moreover, miRNA expression is tissue specific. Obesity leads to a dysregulation of miRNA expression in adipose tissue, and changes in miRNA expression relate to changes in gene expression related to the development of insulin resistance. However, because miRNA can be exported to the extracellular medium through exosomes, proteins, and lipoproteins, miRNA can be found in extracellular fluids like blood, urine, saliva, and cerebrospinal fluid. Considering the above, miRNA have been proposed as biological markers of different
diseases, and also as potential therapeutic targets. 

Abstract

MicroRNAs (miRNAs) are part of the epigenetic mechanisms that regulate gene expression at a post-transcriptional level. This review describes some miRNAs whose expression is modified in obesity and that may be involved in the development of insulin resistance. The metabolic alterations associated with obesity are due to an adipose tissue dysfunction. miRNAs are a mechanism that regulates gene expression, one miRNA can regulate the expression up to a thousand genes, and at the same time one gene can be regulated by several miRNAs; moreover, miRNA expression is tissue specific. Obesity leads to a dysregulation of miRNA expression in adipose tissue, and changes in miRNA expression relate to changes in gene expression related to the development of insulin resistance. However, because miRNA can be exported to the extracellular medium through exosomes, proteins, and lipoproteins, miRNA can be found in extracellular fluids like blood, urine, saliva, and cerebrospinal fluid. Considering the above, miRNA have been proposed as biological markers of different
diseases, and also as potential therapeutic targets. 

Get Citation

Keywords

obesity; microRNA; insulin resistance; adipose tissue; epigenetics

About this article
Title

Expression of miRNA in obesity and insulin resistance: a review

Journal

Endokrynologia Polska

Issue

Vol 72, No 1 (2021)

Article type

Review paper

Pages

73-80

Published online

2021-02-26

DOI

10.5603/EP.a2021.0002

Pubmed

33749820

Bibliographic record

Endokrynologia Polska 2021;72(1):73-80.

Keywords

obesity
microRNA
insulin resistance
adipose tissue
epigenetics

Authors

Paulina Estrella Ibarra
Pablo García-Solís
Juan Carlos Solís-Sáinz
Andrés Cruz-Hernández

References (60)
  1. World Health Organization, Obesity and overweight, 2017. http://www.who.int/mediacentre/factsheets/fs311/en/ (10-Nov-2017).
  2. Goossens GH. The role of adipose tissue dysfunction in the pathogenesis of obesity-related insulin resistance. Physiol Behav. 2008; 94(2): 206–218.
  3. Castoldi A, Naffah de Souza C, Câmara NO, et al. The Macrophage Switch in Obesity Development. Front Immunol. 2015; 6: 637.
  4. Sadashiv I, Tiwari S, Paul BN, et al. Over expression of resistin in adipose tissue of the obese induces insulin resistance. World J Diabetes. 2012; 3(7): 135–141.
  5. Klöting N, Graham TE, Berndt J, et al. Serum retinol-binding protein is more highly expressed in visceral than in subcutaneous adipose tissue and is a marker of intra-abdominal fat mass. Cell Metab. 2007; 6(1): 79–87.
  6. Ayina CN, Noubiap JJ, Etoundi Ngoa LS, et al. Association of serum leptin and adiponectin with anthropomorphic indices of obesity, blood lipids and insulin resistance in a Sub-Saharan African population. Lipids Health Dis. 2016; 15: 96.
  7. Harwood HJ. The adipocyte as an endocrine organ in the regulation of metabolic homeostasis. Neuropharmacology. 2012; 63(1): 57–75.
  8. Lafontan M. Adipose tissue and adipocyte dysregulation. Diabetes Metab. 2014; 40(1): 16–28.
  9. Dalmas E, Clément K, Guerre-Millo M. Defining macrophage phenotype and function in adipose tissue. Trends Immunol. 2011; 32(7): 307–314.
  10. Zou C, Shao J. Role of adipocytokines in obesity-associated insulin resistance. J Nutr Biochem. 2008; 19(5): 277–286.
  11. Park JH, Kim SH, Lee MS, et al. Epigenetic modification by dietary factors: Implications in metabolic syndrome. Mol Aspects Med. 2017; 54: 58–70.
  12. Kim VN. MicroRNA biogenesis: coordinated cropping and dicing. Nat Rev Mol Cell Biol. 2005; 6(5): 376–385.
  13. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2): 281–297.
  14. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell. 2005; 120(1): 15–20.
  15. Kulyté A, Belarbi Y, Lorente-Cebrián S, et al. Additive effects of microRNAs and transcription factors on CCL2 production in human white adipose tissue. Diabetes. 2014; 63(4): 1248–1258.
  16. miRBase v 21. miRBase: the microRNA database. http://www.mirbase.org/cgi-bin/browse.pl?org=hsa ( 02-Jul-2020).
  17. Inui M, Martello G, Piccolo S. MicroRNA control of signal transduction. Nat Rev Mol Cell Biol. 2010; 11(4): 252–263.
  18. Ipsaro JJ, Joshua-Tor L. From guide to target: molecular insights into eukaryotic RNA-interference machinery. Nat Struct Mol Biol. 2015; 22(1): 20–28.
  19. Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012; 13(4): 271–282.
  20. Iwakawa HO, Iwakawa HO, Tomari Y. The Functions of MicroRNAs: mRNA Decay and Translational Repression. Trends Cell Biol. 2015; 25(11): 651–665.
  21. Arner E, Mejhert N, Kulyté A, et al. Adipose tissue microRNAs as regulators of CCL2 production in human obesity. Diabetes. 2012; 61(8): 1986–1993.
  22. Brennan E, Wang Bo, McClelland A, et al. Protective Effect of let-7 miRNA Family in Regulating Inflammation in Diabetes-Associated Atherosclerosis. Diabetes. 2017; 66(8): 2266–2277.
  23. Sung SY, Liao CH, Wu HP, et al. Loss of let-7 microRNA upregulates IL-6 in bone marrow-derived mesenchymal stem cells triggering a reactive stromal response to prostate cancer. PLoS One. 2013; 8(8): e71637.
  24. Jones A, Danielson KM, Benton MC, et al. miRNA Signatures of Insulin Resistance in Obesity. Obesity (Silver Spring). 2017; 25(10): 1734–1744.
  25. Santovito D, De Nardis V, Marcantonio P, et al. Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control. J Clin Endocrinol Metab. 2014; 99(9): E1681–E1685.
  26. Meerson A, Traurig M, Ossowski V, et al. Human adipose microRNA-221 is upregulated in obesity and affects fat metabolism downstream of leptin and TNF-α. Diabetologia. 2013; 56(9): 1971–1979.
  27. Belarbi Y, Mejhert N, Lorente-Cebrián S, et al. MicroRNA-193b Controls Adiponectin Production in Human White Adipose Tissue. J Clin Endocrinol Metab. 2015; 100(8): E1084–E1088.
  28. Derosa G, Fogari E, D'Angelo A, et al. Adipocytokine levels in obese and non-obese subjects: an observational study. Inflammation. 2013; 36(4): 914–920.
  29. Guenther M, James R, Marks J, et al. Adiposity distribution influences circulating adiponectin levels. Transl Res. 2014; 164(4): 270–277.
  30. Lihn AS, Bruun JM, He G, et al. Lower expression of adiponectin mRNA in visceral adipose tissue in lean and obese subjects. Mol Cell Endocrinol. 2004; 219(1-2): 9–15.
  31. Yamauchi T, Kamon J, Minokoshi Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002; 8(11): 1288–1295.
  32. Yoon MJ, Lee GY, Chung JJ, et al. Adiponectin increases fatty acid oxidation in skeletal muscle cells by sequential activation of AMP-activated protein kinase, p38 mitogen-activated protein kinase, and peroxisome proliferator-activated receptor alpha. Diabetes. 2006; 55(9): 2562–2570.
  33. Park Sk, Oh SY, Lee MY, et al. CCAAT/enhancer binding protein and nuclear factor-Y regulate adiponectin gene expression in adipose tissue. Diabetes. 2004; 53(11): 2757–2766.
  34. Senn JJ, Klover PJ, Nowak IA, et al. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes. 2002; 51(12): 3391–3399.
  35. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem. 2003; 278(46): 45777–45784.
  36. Petersen EW, Carey AL, Sacchetti M, et al. Acute IL-6 treatment increases fatty acid turnover in elderly humans in vivo and in tissue culture in vitro. Am J Physiol Endocrinol Metab. 2005; 288(1): E155–E162.
  37. Reilly SM, Saltiel AR. Adapting to obesity with adipose tissue inflammation. Nat Rev Endocrinol. 2017; 13(11): 633–643.
  38. Ortega FJ, Moreno-Navarrete JM, Pardo G, et al. MiRNA expression profile of human subcutaneous adipose and during adipocyte differentiation. PLoS One. 2010; 5(2): e9022.
  39. Ortega FJ, Moreno M, Mercader JM, et al. Inflammation triggers specific microRNA profiles in human adipocytes and macrophages and in their supernatants. Clin Epigenetics. 2015; 7: 49.
  40. Prats-Puig A, Ortega FJ, Mercader JM, et al. Changes in circulating microRNAs are associated with childhood obesity. J Clin Endocrinol Metab. 2013; 98(10): E1655–E1660.
  41. Ortega FJ, Mercader JM, Catalán V, et al. Targeting the circulating microRNA signature of obesity. Clin Chem. 2013; 59(5): 781–792.
  42. Wang YT, Tsai PC, Liao YC, et al. Circulating microRNAs have a sex-specific association with metabolic syndrome. J Biomed Sci. 2013; 20: 72.
  43. Yamauchi T, Nio Y, Maki T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007; 13(3): 332–339.
  44. Lustig Y, Barhod E, Ashwal-Fluss R, et al. RNA-binding protein PTB and microRNA-221 coregulate AdipoR1 translation and adiponectin signaling. Diabetes. 2014; 63(2): 433–445.
  45. Peng J, Zhou Y, Deng Z, et al. miR-221 negatively regulates inflammation and insulin sensitivity in white adipose tissue by repression of sirtuin-1 (SIRT1). J Cell Biochem. 2018; 119(8): 6418–6428.
  46. Cao Y, Jiang X, Ma H, et al. SIRT1 and insulin resistance. J Diabetes Complications. 2016; 30(1): 178–183.
  47. Yoshizaki T, Milne JC, Imamura T, et al. SIRT1 exerts anti-inflammatory effects and improves insulin sensitivity in adipocytes. Mol Cell Biol. 2009; 29(5): 1363–1374.
  48. Shi Z, Zhao C, Guo X, et al. Differential expression of microRNAs in omental adipose tissue from gestational diabetes mellitus subjects reveals miR-222 as a regulator of ERα expression in estrogen-induced insulin resistance. Endocrinology. 2014; 155(5): 1982–1990.
  49. Kouidhi S, Berrhouma R, Rouissi K, et al. Human subcutaneous adipose tissue Glut 4 mRNA expression in obesity and type 2 diabetes. Acta Diabetol. 2013; 50(2): 227–232.
  50. Chuang TY, Wu HL, Chen CC, et al. MicroRNA-223 Expression is Upregulated in Insulin Resistant Human Adipose Tissue. J Diabetes Res. 2015; 2015: 943659.
  51. Deiuliis JA, Syed R, Duggineni D, et al. Visceral Adipose MicroRNA 223 Is Upregulated in Human and Murine Obesity and Modulates the Inflammatory Phenotype of Macrophages. PLoS One. 2016; 11(11): e0165962.
  52. Lee EK, Lee MiJ, Abdelmohsen K, et al. miR-130 suppresses adipogenesis by inhibiting peroxisome proliferator-activated receptor gamma expression. Mol Cell Biol. 2011; 31(4): 626–638.
  53. Sharma AM, Staels B. Review: Peroxisome proliferator-activated receptor gamma and adipose tissue--understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab. 2007; 92(2): 386–395.
  54. Redonnet A, Bonilla S, Noël-Suberville C, et al. Relationship between peroxisome proliferator-activated receptor gamma and retinoic acid receptor alpha gene expression in obese human adipose tissue. Int J Obes Relat Metab Disord. 2002; 26(7): 920–927.
  55. Kursawe R, Narayan D, Cali AMG, et al. Downregulation of ADIPOQ and PPARγ2 gene expression in subcutaneous adipose tissue of obese adolescents with hepatic steatosis. Obesity (Silver Spring). 2010; 18(10): 1911–1917.
  56. Ishida M, Shimabukuro M, Yagi S, et al. MicroRNA-378 regulates adiponectin expression in adipose tissue: a new plausible mechanism. PLoS One. 2014; 9(11): e111537.
  57. Liu L, Li Q, Xiao X, et al. miR-1934, downregulated in obesity, protects against low-grade inflammation in adipocytes. Mol Cell Endocrinol. 2016; 428: 109–117.
  58. Martinelli R, Nardelli C, Pilone V, et al. miR-519d overexpression is associated with human obesity. Obesity (Silver Spring). 2010; 18(11): 2170–2176.
  59. Guiu-Jurado E, Auguet T, Berlanga A, et al. Downregulation of de Novo Fatty Acid Synthesis in Subcutaneous Adipose Tissue of Moderately Obese Women. Int J Mol Sci. 2015; 16(12): 29911–29922.
  60. Heneghan HM, Miller N, McAnena OJ, et al. Differential miRNA expression in omental adipose tissue and in the circulation of obese patients identifies novel metabolic biomarkers. J Clin Endocrinol Metab. 2011; 96(5): E846–E850.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl